Literature DB >> 12537309

THG113: a novel selective FP antagonist that delays preterm labor.

Krishna G Peri1, Christiane Quiniou, Xin Hou, Daniel Abran, Daya R Varma, William D Lubell, Sylvain Chemtob.   

Abstract

PGF2alpha is an important smooth muscle contractile agent that exerts significant effects on myometrium and is implicated in labor. THG113 was recently identified as a PGF2alpha receptor (FP) antagonist. We characterized the specificity and selectivity of THG113, tested its effects on PGF2alpha-induced smooth muscle contraction, and assessed its efficacy in a model of endotoxin (LPS)-induced preterm labor. [125I]THG113 bound specifically to FP-expressing but not to native (not expressing FP) HEK293 cells. In FP-expressing HEK293 cells, THG113 markedly reduced PGF2alpha-elicited phosphoinositide hydrolysis (IC50 27 nM). Similarly, PGF2alpha-evoked microvascular (retinal) contraction was noncompetitively blocked (by > 90%) by THG113. In contrast, contraction to agonists of homologous prostanoid receptors EP1 and TP (17-phenyl-trinor PGE2 and U46619) was unaffected (< 1%) by high concentrations of THG113 (100 micromol/L); THG113 (100 micromol/L) also did not affect contraction to numerous other agents including platelet activating factor, endothelin, and angiotensin II. Force and duration of PGF2alpha-evoked contractions of myometrial strips of pig (non-pregnant, luteal phase) and mouse (immediately postpartum) were markedly reduced by THG113. In an endotoxin-induced preterm mouse model, lipopolysaccharide (50 microg intraperitioneal) injection at 16 days' gestation resulted in 100% delivery within 15 h; in contrast, 70% of those treated with THG113 (1 mg/day) delivered > 24 h later (at 18 days' gestation; term: 19 days). In addition, in mice injected with lipopolysaccharide and treated 6 h later with THG113 (0.1 mg bolus followed by 1 mg/day) 40% delivered > 48 h later. Fetuses of pregnant mice treated with THG113 were born alive, had higher birth weights (1.6 +/- 0.1 v 1.4 +/- 0.05 g), and appeared healthy. This study describes an effective and selective noncompetitive FP antagonist, THG113, which significantly delays preterm delivery; this provides the basis for future investigations for its use in tocolysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12537309     DOI: 10.1053/sper.2002.37307

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  13 in total

Review 1.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

2.  Role of the ERC motif in the proximal part of the second intracellular loop and the C-terminal domain of the human prostaglandin F2alpha receptor (hFP-R) in G-protein coupling control.

Authors:  Andrea Pathe-Neuschäfer-Rube; Frank Neuschäfer-Rube; Gerhard P Püschel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

Review 3.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

4.  A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway.

Authors:  Eugénie Goupil; Danaë Tassy; Carine Bourguet; Christiane Quiniou; Veronica Wisehart; Darlaine Pétrin; Christian Le Gouill; Dominic Devost; Hans H Zingg; Michel Bouvier; Horacio Uri Saragovi; Sylvain Chemtob; William D Lubell; Audrey Claing; Terence E Hébert; Stéphane A Laporte
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

5.  Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure.

Authors:  Martin Leduc; Xin Hou; David Hamel; Melanie Sanchez; Christiane Quiniou; Jean-Claude Honoré; Olivier Roy; Ankush Madaan; William Lubell; Daya R Varma; Joseph Mancini; François Duhamel; Krishna G Peri; Vincent Pichette; Nikolaus Heveker; Sylvain Chemtob
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

6.  Parturition and recruitment of macrophages in cervix of mice lacking the prostaglandin F receptor.

Authors:  Steven M Yellon; Charlotte A Ebner; Yukihiko Sugimoto
Journal:  Biol Reprod       Date:  2007-11-14       Impact factor: 4.285

7.  PG F(2α) Receptor: A Promising Therapeutic Target for Cardiovascular Disease.

Authors:  Jian Zhang; Yanjun Gong; Ying Yu
Journal:  Front Pharmacol       Date:  2010-10-14       Impact factor: 5.810

Review 8.  Functional insights into modulation of BKCa channel activity to alter myometrial contractility.

Authors:  Ramón A Lorca; Monali Prabagaran; Sarah K England
Journal:  Front Physiol       Date:  2014-07-31       Impact factor: 4.566

Review 9.  Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics.

Authors:  Etienne Khoury; Stéphanie Clément; Stéphane A Laporte
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-08       Impact factor: 5.555

10.  THG113.31, a specific PGF2alpha receptor antagonist, induces human myometrial relaxation and BKCa channel activation.

Authors:  Helen C Doheny; Michael J O'Reilly; Donal J Sexton; John J Morrison
Journal:  Reprod Biol Endocrinol       Date:  2007-03-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.